NCT04708236View on ClinicalTrials.gov

A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2021

Primary Completion Date

May 31, 2021

Study Completion Date

July 31, 2021

Conditions
COVID-19
Interventions
DRUG

ORTD-1 low dose

ORTD-1 will be administered intravenously once daily for 5 consecutive days.

DRUG

ORTD-1 mid dose

ORTD-1 will be administered intravenously once daily for 5 consecutive days.

DRUG

ORTD-1 high dose

ORTD-1 will be administered intravenously once daily for 5 consecutive days.

OTHER

Vehicle control

Vehicle Control will be administered intravenously once daily for 5 consecutive days.

Trial Locations (1)

92868

UC Irvine Medical Center, Orange

Sponsors
All Listed Sponsors
lead

Oryn Therapeutics, LLC

INDUSTRY

NCT04708236 - A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia | Biotech Hunter | Biotech Hunter